Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride

Clinical Nephrology

Volumn 73, Issue 6, 2010, Pages 420-425

  Goto, S ^a   Fujii, H ^a   Kim, J I ^b   Fukagawa, M ^a,c  

^a KOBE UNIVERSITY   (Japan)

^b Department of Internal Medicine   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Folic acid; Hemodialysis patients; Homocysteine; Sevelamer hydrochloride

Indexed keywords

CALCIUM CARBONATE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEVELAMER; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DOSE INCREASE; FEMALE; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PHOSPHATE BLOOD LEVEL;

EID: 77952662966     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73420     Document Type: Article

References (25)

1. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288: 2015-2022.
2. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004; 15: 442-453. (Pubitemid 38140786)
3. Suliman ME, Qureshi AR, Bárány P, Stenvinkel P, Filho JC, Anderstam B, Heimbürger O, Lindholm B, Bergström J. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000; 57: 1727-1735. (Pubitemid 30207932)
4. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int. 2006; 69: 331-335. (Pubitemid 43323084)
5. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992; 55: 131-138.
6. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest. 1988; 81: 466-474. (Pubitemid 18075242)
7. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR. Bile acid binding to sevelamer HCl. Kidney Int. 2002; 62: 611-619. (Pubitemid 34779775)
8. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003; 42: 1253-1259. (Pubitemid 37486770)
9. Plone MA, Petersen JS, Rosenbaum DP, Burke SK. Sevelamer, a phosphate-binding polymer, is a nonabsorbed compound. Clin Pharmacokinet. 2002; 41: 517-523.
10. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut. 1975; 16: 93-98.
11. Genzyme Corporation. Renagel (sevelamer hydrochloride) package insert. Cambridge, MA; 2007.
12. Kyowa Hakko Kirin Corporation. Phosblock (sevelamer hydrochloride) pharmaceutical interview form, 9th edition, 2008 (in Japanese).
13. Hoppner K, Lampi B. Bioavailability of folate following ingestion of cholestyramine in the rat. Int J Vitam Nutr Res. 1991; 61: 130-134.
14. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone.Kidney Int. 1999; 55: 299-307.
15. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001; 107: 675-683. (Pubitemid 32225353)
16. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atherosler Suppl. 2003; 4: 61-65. (Pubitemid 38234496)
17. Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. N Engl J Med. 2006; 354: 1629-1632.
18. McCully KS. Vascular pathology of homocysteinemia: implication for the pathogenesis of atherosclerosis. Am J Pathol. 1969; 56: 111-128.
19. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997; 20: 295-300. (Pubitemid 27273492)
20. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. NORVIT Trial Investiga- tors. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354: 1578-1588.
21. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Poque J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354: 1567-1577.
22. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM. Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. JAMA. 2007; 298: 1163-1170.
23. Kane MA, Waxman S. Role of folate binding proteins in folate metabolism. Lab Invest. 1989; 60: 737-746. (Pubitemid 19168983)
24. Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, Plone M, Pritchard N. Arandomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant. 2009; 24: 3794-3799.
25. McKinley MC, Strain JJ, McPartlin J, Scott JM, McNulty H. Plasma homocysteine is not subject to seasonal variation. Clin Chem. 2001; 47: 1430-1436. (Pubitemid 32678822)